We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urinary Volatiles Tested for Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 21 Apr 2017
Early detection is one of the most important factors in helping men to survive prostate cancer, but the diagnosis is not straightforward. More...
It usually relies on a combination of a digital rectal exam and a blood test to measure prostate-specific antigen (PSA) to help decide whether a biopsy should be done.

However, biopsies are expensive, uncomfortable, and carry the risk of infection. Unfortunately, thousands of men undergo the procedure, which involves inserting a needle into the prostate gland to remove pieces of tissue for analysis, only to discover that they do not require cancer treatment.

Scientists from Indiana University-Purdue University tested urine samples collected from 100 men who were undergoing prostate biopsies. They noted that some previous studies had experienced problems with chemical degradation. Thus, to better preserve the samples during analysis, they added sodium chloride and neutralized their pH.

The scientists used gas chromatography-mass spectrometry to analyze the volatile organic compounds in the air above the urine samples, the team found a set of small molecules that appear to be unique to prostate cancer. The molecules were present in 90% of samples from men who were subsequently found to have prostate cancer, but they were not present in samples from men who did not have it.

The investigators researchers are already planning to validate their findings with a large-scale study involving several health centers. They also hope to compare their findings with results obtained from dogs, with the help of a local dog trainer. They suggest, if these further tests confirm their findings, that their chemical sniff test will be available for clinical use within the next few years.

Amanda P. Siegel, PhD, a lead investigator, said, “If dogs can smell prostate cancer, we should be able to, too. We hope our studies will help doctors and patients make better-informed decisions about whether to have a biopsy, and to avoid unwarranted procedures.” The study was presented at the 253rd American Chemical Society Meeting, held April 2-6, 2017, in San Francisco, CA, USA.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The liquid biopsy approach measures randomness in DNA methylation patterns to detect early-stage cancer signals in blood (Photo courtesy of 123RF)

Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability

Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.